ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Evaluation of GPA, molGPA and prognostic factors in melanoma brain metastases: a single-center study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum lactate dehydrogenase is associated with the presence and extent of preoperative peritumoral edema in melanoma brain metastases.Journal of neuro-oncology · 2026Article
- Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant melanoma ranks among the leading causes of brain metastases (BM). The Graded Prognostic Assessment (GPA) and the melanoma-specific molecular GPA (molGPA) are well-established prognostic tools that help estimate survival and guide therapeutic decisions. This single-center, retrospective clinical study aimed to evaluate prognostic factors for overall survival (OS), intracranial tumor control (IC), and intracranial progression-free survival (IPFS), as well as GPA and molGPA within a real-world clinical setting.
methodsPatients with melanoma-associated BM who underwent radiotherapy (RT) between January 2016 and December 2023 were included. Study endpoints included OS, IC, and IPFS, with OS and IPFS analyzed across the entire cohort (n = 59) and IC was evaluated in cases with follow-up imaging (n = 47).
resultsThe median survival of all patients was 6.9 months (IQR 2.2; 23.6). Regarding OS, three predictive factors were significantly associated with the survival probability: a Karnofsky performance status index (KPS) <70 (p = 0.003), a GPA score of 0-1.0 versus 1.5-4.0 (p = 0.002) and a molGPA score of 0-1.0 versus 1.5-4.0 (p= 0.034). Intracranial progression-free survival was significantly decreased in patients with KPS <70 (p = 0.01), multiple brain metastases (p = 0.036), and GPA scores of 0-1.0 (p = 0.011).
conclusionsBoth GPA and molGPA were validated as significant predictors of OS in patients with melanoma-associated BM. However, GPA emerged as the sole score significantly associated with both OS and IPFS, suggesting a potential advantage in its clinical utility. The validation of GPA and molGPA as significant predictors for OS in a real clinical setting support their use in guiding treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.